Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Nexstim

8.88 EUR

+0.68 %

5,638 following
Corporate customer

NXTMH

First North Finland

Medical Equipment & Services

Health Care

+0.68 %
-21.42 %
-37.46 %
-37.02 %
-30.08 %
+9.36 %
+137.12 %
+26.86 %
-98.53 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
64.05M EUR
Turnover
131.26K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
27.02.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 27.02.2026

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
30.3.
2026

General meeting '26

14.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
University Hospital in Finland Orders a Nexstim NBS 6 System Press release, Helsinki, 10 March 2026 at 9 AM (EET) Nexstim Plc (“Nexstim” or “Company”) has received an order for an NBS 6 diagnostics system from a university hospital in Finland. The customer is an experienced Nexstim...
3/10/2026, 7:02 AM
by Kyhnykeisari
32
The TMS therapy market is said to grow at a 9–10% CAGR far into the future. Brainsway and Nexstim are indeed growing significantly faster. Brainsway’s turnaround has rewarded its owners with 1,300% share price growth over 3 years. If Nexstim’s earnings grow rapidly in the coming ...
yesterday
by Ledificazione
24
In my opinion, Brainsway has successfully demonstrated that in the TMS industry, it is easy to continue growing a strong result after a profitability turnaround. They released last year’s results yesterday: Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million...
yesterday
by Kyhnykeisari
24
An interesting summary article on the efficacy, benefits, pricing, pharmacological treatment, and more regarding TMS in relation to Alzheimer’s. Based on 143 studies and 5,800 patients. cognitivefxusa.com Treatment for Brain Fog after Chemo, Cognitive Decline Research Struggling ...
3/11/2026, 8:29 AM
by AccionHombre
22
Nexstim has a small stake in Sinaptica… it could prove to be valuable at some point. Nexstim is available at 8.50 today. Is it starting to be time to add?
3/9/2026, 8:26 AM
by Puutaheinää
11
Could this be it: hankintailmoitukset.fi Hilma
3/10/2026, 2:19 PM
5
Medical tech should otherwise be immune, but rising interest rates obviously have an impact. I’m still a bit surprised that they are among the top decliners.
3/9/2026, 11:00 AM
by Puutaheinää
5
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.